Medical Developments International (ASX:MVP) share price on watch as losses widen

Medical Developments International has handed in its half year results…

Key points
  • Medical Developments International has released its half year results and reported a decline in revenue and wider losses
  • Though, its top line performance isn't as bad as you think if you dig deeper
  • Penthrox (green whistle) sales were strong during the half

The Medical Developments International Ltd (ASX: MVP) share price will be on watch on Friday.

This follows the release of the healthcare company's half year results after the market close.

A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.

Image source: Getty Images

Medical Developments International share price on watch after big loss

  • Revenue down 23% to $9.865 million
  • Net loss after tax widened from $1.1 million to $7.4 million
  • Cash and cash equivalents of $28.3 million

What happened during the first half?

For the six months ended 31 December, Medical Developments International reported a 23% decline in revenue to $9.865 million. This decline was entirely due to $6.4 million in non-recurring contract income recorded during the prior corresponding period. This overshadowed a 55% increase in core sales, supported by a 131% jump in Australian Penthrox sales.

On the bottom line, Medical Developments International generated a net loss after tax of $7.4 million, compared to a loss of $1.1 million a year earlier. Though, after adjusting for non-operating items, the company's loss was comparable to the prior period.

No dividend was declared for the half once again.

Management commentary

Medical Developments International's Chair, Gordon Naylor, was pleased with the progress the company made during the half.

He said: "I continue to be pleased with the progress being made by Brent and his leadership team to reshape and focus MVP. It is especially encouraging to see early signs that the approach is working. Despite the pandemic challenges, Penthrox sales growth is strong in Europe, our primary growth corridor over the next few years. We're also seeing solid underlying growth in Australian sales and our US respiratory franchise."

"Our renewed focus has meant that we have taken formal decisions to cease further development of continuous flow processes for third parties and to exit the Veterinary segment, allowing our skilled resources to be applied to the core pain segment."

"In another positive development, our next generation Penthrox delivery device ('Selfie') has reached the milestone of formal project approval. Our aim is for Selfie to propel further future business growth. I thank Brent and the MVP team who have been through a challenging time. The challenges aren't over, but I am confident that the company is heading in the right direction," Mr Naylor added.

No guidance has been provided for the remainder of FY 2022.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man leans forward propped on his elbows as he holds his clasped hands to his mouth in a worried pose as he gazes at his computer screen in a home setting.
Earnings Results

5 things reporting season taught ASX investors about FY27

Five FY26 lessons that shape the year ahead.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Earnings Results

This broker is tipping 33% upside for Megaport shares

It could be time to buy the dip on Megaport shares.

Read more »

Elderly couple using laptop at home while drinking a cup of coffee.
Earnings Results

Why now is the time to buy MediBank Private shares: Expert

This stock comes with a strong yield and defensive profile.

Read more »

A gambler at a casino bets a pile of chips on one number.
Earnings Results

The Star Entertainment share price falls on FY26 earnings

The Star Entertainment Group posted a $307 million net loss for FY26, but cost cuts and stabilised revenues mark early…

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Financial Shares

Kina Securities lifts profit and dividend in half-year 2026 earnings

Kina Securities lifts 1H 2026 profit and dividend, buoyed by strong capital and digital initiatives.

Read more »

Businessman planning and analysing investment data.
Earnings Results

Kingsgate Consolidated posts record FY2026 earnings

NPAT jumps 843% and a dividend is declared on record gold and silver production.

Read more »

Woman at computer in office with a view
Earnings Results

Praemium posts FY26 revenue growth and completes platform integration

Praemium’s FY26 results show revenue growth, HNW momentum, and successful tech integration driving future opportunities.

Read more »

happy group of people
Earnings Results

Black Cat Syndicate posts record FY26 earnings and profit turnaround

Black Cat Syndicate reports record FY26 results, including a $374 million revenue surge and $86 million profit turnaround on strong…

Read more »